Electrolyte abnormalities according to laboratory assessment1

Electrolyte abnormalities according to laboratory assessment at incidence rate >10% and a >2% difference between arms in patients receiving Portrazza in the SQUIRE trial

Incidence of electrolyte abnormalities chart
Zoom In
Zoom Out

*Only patients with baseline and at least one post-baseline result are included.

  • The median time to onset of hypomagnesemia was 6 weeks (25th percentile 4 weeks; 75th percentile 9 weeks)1
  • Hypomagnesemia was reported as resolved in 43% of the patients who received Portrazza1
  • In SQUIRE, 32% of the patients in the Portrazza arm and 16% of the patients who received gemcitabine and cisplatin alone received magnesium replacement1

Reference: 1. Portrazza (necitumumab) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2015.